8-K: Predictive Oncology Enacts 1-for-15 Reverse Stock Split

Predictive Oncology Inc. has implemented a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective September 29, 2025.

Summary

• Stockholders approved a 1-for-15 reverse stock split of common stock.
• The reverse stock split becomes effective at 5:00 PM ET on September 29, 2025.
• Common stock will begin trading on a reverse-split-adjusted basis on the Nasdaq Capital Market at the open of trading on September 30, 2025, under the existing ticker symbol POAI.
• The primary purpose is to comply with Nasdaq's minimum bid price requirement to maintain listing.
• No fractional shares will be issued; any resulting fractional shares will be rounded up to the next whole number.
• The total number of authorized shares of common stock or preferred stock remains unchanged.
• Stockholders also approved the issuance of up to $10,000,000 of common stock under a Standby Equity Purchase Agreement dated July 1, 2025, for Nasdaq listing rule 5635 compliance.
• Prior to the split, 11,436,201 shares were outstanding; immediately after, approximately 762,414 shares will be outstanding, subject to rounding.

Sentiment

Score: 4

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing, which is a positive for continued market access. However, the underlying reason for the split (low stock price) and the potential for future dilution from the approved capital raise are negative indicators. The company's core business in AI-driven drug development is promising, but this filing focuses on a compliance issue rather than operational successes.

Positives

• The company is taking action to maintain its Nasdaq listing, which is crucial for liquidity and investor confidence.
• Stockholders approved a proposal to issue up to $10,000,000 of common stock, potentially providing future capital.
• Fractional shares resulting from the split will be rounded up, benefiting affected stockholders.

Negatives

• The necessity of a reverse stock split indicates a sustained low stock price, which is generally viewed negatively by the market.
• The reverse split does not fundamentally change the company's market capitalization or underlying value, only the number of shares and price per share.
• The approval of a potential $10,000,000 common stock issuance could lead to future dilution for existing shareholders.

Risks

• There is no assurance that the company will regain or maintain compliance with Nasdaq's minimum bid price requirement.
• Continued non-compliance or delisting from Nasdaq would materially and adversely affect the company's ability to raise capital and its financial condition and business.
• The process of addressing Nasdaq compliance involves substantial costs and diversion of personnel's attention and resources.
• Actual future performance may materially differ from contemplated forward-looking statements due to various factors, including market conditions and operational challenges.

Future Outlook

The company aims to regain and maintain compliance with Nasdaq's minimum bid price requirement through the reverse stock split. There is also an approved mechanism for a potential future capital raise of up to $10,000,000 through a Standby Equity Purchase Agreement. However, the company cautions that there is no assurance of regaining compliance and that continued non-compliance or delisting would materially and adversely affect its ability to raise capital and its financial condition.

Management Comments

• Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
• The company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound.

Industry Context

Predictive Oncology operates in the highly competitive and capital-intensive AI-driven drug development and discovery sector. The use of AI and machine learning is a significant trend in the pharmaceutical industry, aiming to accelerate drug discovery and improve success rates. Maintaining a Nasdaq listing is crucial for companies in this sector to attract investment and maintain visibility, especially given the long development cycles and high costs associated with drug development.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a 1-for-15 ratio, with the per-share price proportionally increasing. Fractional shares will be rounded up. Their percentage ownership remains largely the same, but potential future dilution from the $10M capital raise is possible. Maintaining Nasdaq listing benefits liquidity.
• Employees: No direct impact mentioned, but maintaining Nasdaq listing can contribute to company stability and access to capital for operations.
• Customers/Partners: No direct impact mentioned. The company's core business operations in AI-driven drug development continue.
• Creditors: No direct impact mentioned.

Next Steps

• Common stock will begin trading on a reverse-split-adjusted basis on the Nasdaq Capital Market as of the open of trading on September 30, 2025.
• The company will continue efforts to maintain compliance with Nasdaq listing rules.
• Pacific Stock Transfer will send stockholders transaction statements indicating new share counts.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing, which is a positive for the company's market presence and ability to raise capital. However, it addresses a symptom (low stock price) rather than underlying operational performance. The approval of a potential $10 million capital raise provides flexibility but also signals a need for funding and potential future dilution. Investors should hold to observe if the company can leverage its AI-driven drug development platform for tangible financial improvements and sustained Nasdaq compliance, as the current action is primarily defensive.

Keywords

Predictive Oncology, POAI, Reverse Stock Split, Nasdaq Compliance, AI Drug Discovery, Biotechnology, Oncology, Stock Split, SEC Filing, Capital Market